<DOC>
	<DOCNO>NCT00400504</DOCNO>
	<brief_summary>Patients malignancy high risk develop thromboembolic complication treatment chemo- radiation therapy enhance risk . Conventional haemostatic test suitable screen tool hypercoagulable state . A hypercoagulable profile identify whole blood Thrombelastograph ( TEG ) Analyzer parameter maximal amplitude ( MA ) report correlate thrombotic event patient undergo major non-cardial surgery recurrent ischemic event patient undergo percutaneous coronary intervention . In study investigate correlation TEG measurements thromboembolic event patient newly diagnose malignancy . The hypothesis study : 1 . Patients malignancy hypercoagulability , define TEG MA &gt; 69 mm /or R &lt; 4 min increase risk develop thromboembolic complication compare MA &lt; 69 mm and/or R &gt; 4 min . 2 . Hypercoagulability hence TEG R MA value affect treatment instituted patient ( chemo radiation therapy ) render patient hypercoagulable hence increase risk develop thrombotic complication .</brief_summary>
	<brief_title>Hypercoagulability Thromboembolic Risk Patients With Malignant Disease , Evaluated Thrombelastograph ( TEGÂ® )</brief_title>
	<detailed_description />
	<mesh_term>Thrombophilia</mesh_term>
	<criteria>Clinical diagnosis cancer Mamma cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Thrombelastograph</keyword>
	<keyword>Cancer</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Hypercoagulable</keyword>
</DOC>